SYNNECT®

Smart Injection Solution

When close monitoring of injected medications is required, the **SYNNECT** platform provides injection information via a mobile app. This app uploads real-time data to the cloud to benefit patient treatment and health, pharma and CRO companies that conduct clinical trials where injection information is critical to the success of multimillion-dollar drugs, and payers that require adherence data to track that patients are actually injecting high-cost medications.

Key Features:

- An add-on connectivity drug delivery device
- Indicating injection progress (by volume), on top of injection completion
- Real-time connection to a mobile app, data transferred to a secured cloud database
- Compatible with prefilled and safety syringes
- Can be integrated with DALI's SAN® product line: SAN-L, SAN-P, SAN-Light, SAN-In, SAN-DV and SAN-DV Pro

SYNNECT® Benefits - Value Based Medicine

For the Pharma Company

- Fits injectable drugs' main primary packaging forms
- Accurate database for actual treatment given
- · Provides reimbursement evidence
- Could be used for adverse events data collection
- The database is helpful for users' behavior analysis
- As an add-on connected drug delivery device low regulatory hurdles

For the HCP and HMO

- · Close monitoring on patients adherence to treatment
- Real-time reporting on drug administration problems
- Prevent problems before they occur reduced clinic visits and hospitalizations, leading to reduced healthcare costs

For the User

- Patient empowerment facilitates care at the home environment
- Digital and handy IFU brief
- Visualization of injection process
- Real-time indication for successful drug administration
- The platform provides reminders for next dose injection and alerts





Case Study:

SYNNECT® Disrupting the Injectable Drugs' Clinical Trials

The Need

The clinical trials' dropout rate is around 30% in average. This results in high costs, due to additional patients' recruitment and logistic replenishment.

The major contributing factors to the existing high dropout rate are:

- · Patients inconvenience
- Skipped appointments
- Incomplete raw data

The Solution - SYNNECT

Incorporating a connected drug delivery device as part of a clinical study enables the patients to be treated at a home environment, with less clinic appointments. Homecare puts less burden on the patients, and hence they will be more willing to participate in such studies.

Real-time dose administration reporting to the CRO using a connected drug delivery device provides accurate raw data for effective clinical trial monitoring. As a result, problems are immediately solved, and less patients are excluded from the study.

Focusing on data integrity, the automatically generated data is used for further analysis, reducing the need for extensive manual labor and documents handling.



* International patents pending

About DALI Medical Devices

DALI Medical Devices focuses on the development of drug delivery technologies from product concept to commercialization.

The addition of a DALI injector boosts the value of the medication with reduced perception of pain, less anxiety, and better adherence to treatment plans.

Active in the drug delivery arena for over 20 years. One of the injectors we invented and developed was launched in the market by a major pharma company with a blockbuster biologic.

In addition, a customized version of SAN-Light was CE marked for an EU Pharma company.

Contact us:

Mr. David Daily, CEO & Co-Founder | ddaily@dalimed.com | T. +972-8-3730080 Mr. Ziv Cahani, VP, Business Development and Marketing | zcahani@dalimed.com | +972-54-6819341 www.dalimed.com

